IDEXX Laboratories Inc (IDXX)
NASDAQ · Healthcare · Diagnostics & Research
IDEXX Laboratories Inc is a Healthcare company with a market capitalization of $43.98B and a trailing P/E ratio of 39.2.
5-Year Price History
Latest Annual Financials · FY ending December 31, 2025
Recent Quarterly Earnings (EPS)
| Quarter | Reported | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| Q2 2026 | August 4, 2026 | $4.27 | $3.95 | +8.1% |
| Q1 2026 | May 5, 2026 | $3.47 | $3.41 | +1.8% |
| Q4 2025 | February 2, 2026 | $3.08 | $2.94 | +4.8% |
| Q3 2025 | November 3, 2025 | $3.40 | $3.15 | +7.9% |
| Q2 2025 | August 4, 2025 | $3.63 | $3.30 | +10.0% |
| Q1 2025 | May 1, 2025 | $2.96 | $2.84 | +4.2% |
Short Interest
FINRA-reported short interest for semi-monthly settlement dates, published about nine business days after each settlement. Share counts are adjusted to the current split basis.
| Settlement | Shares Short | % of Shares Out | Days to Cover | Change |
|---|---|---|---|---|
| July 15, 2026 | 2,100,008 | 2.60% | 3.0 | +8.3% |
| June 30, 2026 | 1,939,622 | 2.40% | 2.5 | -9.4% |
| June 15, 2026 | 2,139,972 | 2.65% | 3.8 | -1.8% |
| May 29, 2026 | 2,178,333 | 2.70% | 3.4 | +7.8% |
| May 15, 2026 | 2,019,808 | 2.50% | 3.0 | -3.0% |
| April 30, 2026 | 2,082,179 | 2.58% | 3.8 | +0.9% |
| April 15, 2026 | 2,064,422 | 2.56% | 4.1 | +8.2% |
| March 31, 2026 | 1,908,770 | 2.37% | 3.8 | +6.0% |
Other Diagnostics & Research Stocks
Frequently Asked Questions
What is IDEXX Laboratories Inc's market cap?
As of August 13, 2026, IDEXX Laboratories Inc (IDXX) has a market capitalization of $43.98B.
What is IDEXX Laboratories Inc's P/E ratio?
IDEXX Laboratories Inc trades at a trailing price-to-earnings (P/E) ratio of 39.2. Its forward P/E is 37.8.
Does IDEXX Laboratories Inc pay a dividend?
IDEXX Laboratories Inc does not currently pay a dividend.
What sector is IDXX in?
IDEXX Laboratories Inc is in the Healthcare sector, specifically the Diagnostics & Research industry.
What is IDEXX Laboratories Inc's short interest?
As of the July 15, 2026 FINRA settlement, 2,100,008 IDXX shares were sold short, or 2.60% of shares outstanding. Days to cover: 3.0. FINRA publishes short interest twice a month, about nine business days after each settlement date.
What was IDEXX Laboratories Inc's revenue?
In its latest reported fiscal year (ending December 31, 2025), IDEXX Laboratories Inc reported revenue of $4.30B and net income of $1.06B.
Ask your own questions about IDXX
Try mrmarket.ai freeData as of August 13, 2026. Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.